Novel therapeutic combination targets the growth of letrozole-resistant breast cancer through decreased cyclin b1

HIGHLIGHTS

  • who: Jankiben R. Patel and colleagues from the Division of Basic Sciences, College of Pharmacy and Pharmaceutical Sciences, Florida AandM University, Tallahassee, FL, USA have published the article: Novel Therapeutic Combination Targets the Growth of Letrozole-Resistant Breast Cancer through Decreased Cyclin B1, in the Journal: Nutrients 2023, 15, 1632. of 24/03/2023
  • what: Although the study demonstrates potentiation between lapatinib and glyceollin in AI-resistance, it remains unclear whether the pre-clincal impact of combination therapy on the cancer stem_cell niche will translate to a durable clinical response in the metastatic setting.
  •  

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?